49 results on '"Gill, Jasvinder"'
Search Results
2. Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control
3. Insulin Glargine 300 U/Ml is Associated with Less Weight Gain while Maintaining Glycemic Control and Low Risk of Hypoglycemia Compared with Insulin Glargine 100 U/Ml in an Aging Population with Type 2 Diabetes
4. Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program
5. Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/ml versus insulin degludec 100 U/ml using the BRAVO diabetes model
6. Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 units/mL or Detemir 100)
7. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs
8. Calcium uptake by platelets in relation to the aetiology and treatment of vascular disease
9. Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
10. 812-P: Real-World Persistence, Adherence, Health Care Resource Utilization (HRU) , and Hypoglycemia in People with Type 2 Diabetes (T2D) Continuing the 2nd-Generation (2nd-Gen) Basal Insulin (BI) (Glargine 300 U/mL [Gla-300]) vs. Switching to a 1st-Generation (1s)
11. Real‐world outcomes of addition of insulin glargine 300 U/ mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study
12. Real-World-Ergebnisse der Zugabe von Insulin glargin 300 E/ml (Gla-300) zur GLP-1RA-Therapie bei Menschen mit Typ-2-Diabetes (T2D): Die DELIVER-G-Studie
13. Author response for 'Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study'
14. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin
15. Real-world outcomes in people with type 2 diabetes (PWD2) and renal impairment receiving insulin glargine 300 U/mL (Gla-300) and insulin degludec 100U/mL or 200U/mL (IDeg): the DELIVER-R study
16. 7-year Simulation of Clinical Outcomes In People With Type 2 Diabetes Treated With Insulin Glargine 300 U/mL vs 100 U/mL
17. Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study
18. Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs
19. Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study.
20. 105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study
21. 103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1
22. Cover Image, Volume 22, Issue 11
23. A pragmatic randomized clinical trial of insulin glargine 300 U/mLvs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of theACHIEVEControl study
24. Comparative Effectiveness of Basal-Bolus Versus Premix Analog Insulin on Glycemic Variability and Patient-Centered Outcomes during Insulin Intensification in Type 1 and Type 2 Diabetes: A Randomized, Controlled, Crossover Trial
25. OUTCOMES ASSOCIATED WITH INSULIN THERAPY DISRUPTION AFTER HOSPITAL DISCHARGE AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAD USED INSULIN BEFORE AND DURING HOSPITALIZATION
26. Insulin glargine 300 U/mLversus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes ofACHIEVEControl, a prospective, randomized, pragmatic real‐life clinical trial
27. 1038-P: Insulin Glargine 300 U/ml (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life Achieve Control S
28. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring
29. Traditional fuels and cooking stoves in developing countries : a technical, social and environmental assessment
30. 1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study
31. Abstract #322 Impact of Background Sulfonylurea Therapy on Attainment of A1C Targets Without Hypoglycemia in Insulin-Naïve Patients with Type 2 Diabetes Receiving Insulin Glargine 300u/Ml Vs other Basal Insulins in the Achieve Control Pragmatic Real-Life Study
32. A pragmatic randomized clinical trial of insulin glargine 300 U/ mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
33. Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
34. Differential Alterations of Spontaneous and Stimulated 45Ca 2+ Uptake by Platelets from Patients with Type I and Type II Diabetes Mellitus
35. Abstract #1139: Improved Treatment Engagement Among Patients Receiving Insulin Glargine 300 Units/Ml Who Enrolled and Received Live Support Through the Coach Patient Support Program
36. Abstract #298: Maintaining Glycemic Control on GLA-300 While Decreasing Hypoglycemia in an Aging Type 2 Diabetes (T2D) Population: 12-Month Results (Edition 2, Edition 3)
37. Abstract #1315: Reduced Hypoglycemia and Comparable Efficacy with Insulin Glargine 300 U/Ml Vs Insulin Glargine 100 U/Ml in Insulin-Naive Type 2 Diabetes Subjects in Relation To Pre-Breakfast Selfmonitored Plasma Glucose Levels
38. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes
39. Abstract #1220: Reduced Hypoglycemia is Observed with Inhaled Insulin Versus Subcutaneous Insulin Aspart in Patients (Pts) with type 1 Diabetes Mellitus (T1Dm)
40. Abstract #1214: Decreasing Hypoglycemia Without Compromising Efficacy in an Aging Type 2 Diabetes Mellitus (T2Dm) Population
41. Comparing Patient Preferences and Healthcare Provider Recommendations with the Pen Versus Vial-and-Syringe Insulin Delivery in Patients with Type 2 Diabetes
42. Does Pen Help? A Real-World Outcomes Study of Switching from Vial to Disposable Pen Among Insulin Glargine-Treated Patients with Type 2 Diabetes Mellitus
43. Outcomes Associated with Post-Discharge Insulin Continuity in US Patients with Type 2 Diabetes Mellitus Initiating Insulin in the Hospital
44. Comparative Effectiveness of Basal-BolusVersusPremix Analog Insulin on Glycemic Variability and Patient-Centered Outcomes during Insulin Intensification in Type 1 and Type 2 Diabetes: A Randomized, Controlled, Crossover Trial
45. Differential Alterations of Spontaneous and Stimulated 45Ca2+ Uptake by Platelets from Patients with Type I and Type II Diabetes Mellitus
46. Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and 45Ca2+ uptake by human platelets
47. Expression of Voltage-Gated Calcium Channels in Tumor Cell Lines of Neuroectodermal or Other Origin.
48. Effect of milrinone on thromboxane A 2 synthesis, cAMP phosphodiesterase and 45Ca 2+ uptake by human platelets
49. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.